Cord blood cells take on lymphoma: new hope for relapsed patients
NCT ID NCT06707259
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new therapy made from cord blood immune cells (CAR NK cells) designed to target and kill B-cell lymphoma cells. It is for patients whose cancer has not responded to or has returned after standard treatments. The study will check safety and how well the cells work in 24 adults aged 18-75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cord blood-derived CAR NK cells (anti-CD19 with IL-10/IL-15)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat B-cell lymphoma who have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 24 participants, so safety and effectiveness are not yet proven. There may be side effects like cytokine release syndrome or the therapy may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can donor immune cells be engineered to fight blood cancer?